EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Macrophage‐Derived 7‐Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma

Xiaomin Li, Zhilong Li, Jinfang Zhai, Binbin Zou

IUBMB Life · 2025

DOI: 10.1002/iub.70079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Xiaomin Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm, Biomarkers, Tumor. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation for Young Scientists of Shanxi Province, Shanxi Provincial Health Commission, Doctoral Research Fund of Shanxi Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to identify a novel prognostic signature derived from an EGFR Tyrosine kinase inhibitors (TKI‐resistant) macrophage subpopulation and to evaluate its clinical and therapeutic relevance in HCC. We utilized single‐cell RNA sequencing data from HCC patients. An EGFR‐TKI resistance score was calculated across all cell types. Macrophages, which exhibited the highest resistance score, were sub‐clustered to identify the most resistant subpopulation. Marker genes from this sub‐cluster were intersected with differentially expressed genes (DEGs) from the TCGA‐LIHC cohort. A robust prognostic model was constructed. The model's performance was rigorously validated, and the signature was further characterized through multi‐omics analysis and its correlation with immune checkpoint blockade (ICB) response and drug sensitivity. scRNA‐seq analysis unequivocally identified macrophages as possessing the highest EGFR‐TKI resistance score. We identified seven key prognostic genes: SLC41A3 , DCAF13 , PPM1G , NDC80 , FAM83D , FUCA2 , and UQCRH . A risk model built on these seven genes effectively stratified patients into high‐ and low‐risk groups with significantly different overall survival (OS) in the TCGA cohort, a finding successfully validated in the independent GSE76427 cohort. A clinical nomogram integrating the risk score demonstrated excellent predictive accuracy, with AUC values for 1‐, 3‐, and 5‐year OS of 0.816, 0.781, and 0.799, respectively. The low‐risk group was associated with a favorable immune‐infiltrated phenotype and was predicted to be more sensitive to immunotherapy. Conversely, the high‐risk group exhibited distinct genomic features and was predicted to be more sensitive to specific targeted agents, including Navitoclax and Sorafenib. We identified and validated a novel 7‐gene prognostic signature derived from a subpopulation of EGFR‐TKI‐resistant macrophages. This signature accurately predicts patient survival, offers insights into the molecular mechanisms of therapy resistance in HCC, and provides a promising tool for improved patient stratification and the development of personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDrug Resistance, NeoplasmBiomarkers, TumorMacrophagesTranscriptomeHumansPrognosisGene Expression Regulation, NeoplasticProtein Kinase InhibitorsMaleFemaleErbB ReceptorsMiddle Aged

Stichwörter der Autor:innen

EGFR tyrosine kinase inhibitor resistanceLASSOhepatocellular carcinomamacrophagesprognostic signaturesingle‐cell RNA sequencingtumor microenvironment

Substanzen

Biomarkers, TumorProtein Kinase InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • General Surgery Department, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
  • Thoracic Surgery Department, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
  • Respiratory Department, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
  • Rheumatology Department, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
  • Academy of Medical Sciences, Shanxi Medical University, Taiyuan, China.

Förderung

  • Natural Science Foundation for Young Scientists of Shanxi Province
  • Shanxi Provincial Health Commission
  • Doctoral Research Fund of Shanxi Cancer Hospital
  • Shanxi Provincial Health Commission Scientific Research Project Plan
  • Shanxi Bethune Hospital Scientific Research Project Plan Academy Level Scientific Research Fund
  • Shanxi Medical University Provincial Doctoral Fund Project
  • Natural Science Foundation of Shanxi Province
  • Shanxi Bethune Hospital "136" Hospital-level Open Fund

Zitieren

APA

Li, X., Li, Z., Zhai, J., & Zou, B. (2025). A Macrophage‐Derived 7‐Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma. IUBMB Life. https://doi.org/10.1002/iub.70079

Vancouver

Li X, Li Z, Zhai J, Zou B. A Macrophage‐Derived 7‐Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma. IUBMB Life. 2025. doi:10.1002/iub.70079

BibTeX
@article{Li2025,
  author = {Li, Xiaomin and Li, Zhilong and Zhai, Jinfang and Zou, Binbin},
  title = {A Macrophage‐Derived 7‐Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.70079}
}
Kostenlos starten →